Skip to main content
Zai Lab Limited logo

Zai Lab Limited — Investor Relations & Filings

Ticker · 9688 ISIN · KYG9887T1168 LEI · 549300P2UYQ9U5LY1T58 HKEX Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2023-07-07 Board/Management Inform…
Country KY Cayman Islands
Listing HKEX 9688

About Zai Lab Limited

http://www.zailaboratory.com

Zai Lab Limited is an innovative, research-based, commercial-stage biopharmaceutical company dedicated to discovering, developing, and commercializing transformative therapies that address medical conditions with significant unmet needs. The company focuses its pipeline and development efforts across four core therapeutic areas: oncology, immunology, neuroscience, and infectious disease. Zai Lab employs a strategy of internal research and global partnerships to advance best-in-class and first-in-class medicines. A key commercial product is ZEJULA (niraparib), utilized as a maintenance treatment for ovarian cancer in markets including mainland China.

Recent filings

Filing Released Lang Actions
CHANGE OF CHIEF FINANCIAL OFFICER
Board/Management Information Classification · 100% confidence The document is an announcement regarding a change in the company's Chief Financial Officer, detailing the promotion of Dr. Yajing Chen and the departure of Mr. William Cho. It does not contain financial data, report content, or regulatory filings beyond this management change. The content fits the category of Board/Management Information, as it announces a change in senior management personnel.
2023-07-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2023
Regulatory Filings Classification · 95% confidence The document is a detailed monthly report on movements in securities, specifically focusing on changes in authorised and issued share capital, share options, awards, and other share-related activities for Zai Lab Limited. It includes data on share capital, share options exercised, shares issued, and confirmations related to securities issuance. The document is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with the Exchange Listing Rules. It is not an annual or quarterly financial report, nor is it a call transcript, audit report, or management report. It is a regulatory submission detailing share capital movements and share issuance activities for a specific month (June 2023). This type of document fits the category of Regulatory Filings (RNS), as it is a regulatory announcement about share capital changes and securities movements that do not fall under other specific categories like share issue announcements (SHA) or director dealings (DIRS). The document is comprehensive and not a brief announcement or a report publication notice, so RNS is appropriate.
2023-07-06 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zai Lab Limited regarding the grant of share options and restricted share units under the 2022 Equity Incentive Plan. It details the number of options and restricted share units granted, vesting periods, exercise prices, and other terms related to equity compensation for employees. The document references compliance with Listing Rules and provides definitions related to the equity plan. There is no indication that this is a full financial report, audit report, or earnings release. It is not a report publication announcement since it contains substantive information about the share grants themselves. The content fits the category of a Capital/Financing Update as it relates to changes in the company's capital structure through share option and restricted share unit grants.
2023-07-04 English
OVERSEAS REGULATORY ANNOUNCEMENT
Regulatory Filings Classification · 95% confidence The document is a regulatory announcement made by Zai Lab Limited pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. It includes a Form 8-K filing with the U.S. Securities and Exchange Commission dated June 30, 2023. The content primarily announces the approval of a Biologics License Application by China's National Medical Products Administration for a drug, VYVGART, and includes a press release as an exhibit. The document is an official regulatory announcement of a material event (drug approval) and references a Form 8-K filing, which is a current report rather than a full financial report or earnings release. It does not contain financial statements or detailed financial analysis but is a regulatory disclosure of a significant corporate event. The document length is about 15,000 characters, but the content is focused on the announcement of the approval and the filing of the Form 8-K, not the report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-07-02 English
INSIDE INFORMATION - THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVED THE BIOLOGICS LICENSE APPLICATION FOR VYVGART FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVIS
Regulatory Filings Classification · 95% confidence The document is an announcement by Zai Lab Limited regarding the approval of a Biologics License Application by China's National Medical Products Administration. It is labeled as "INSIDE INFORMATION" and is made pursuant to listing rules and inside information provisions. The content focuses on regulatory approval news rather than financial data, management changes, or shareholder voting results. The document is relatively short (2920 characters) and serves as a regulatory announcement about a product approval, not a financial report or detailed presentation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-30 English
GRANT OF RESTRICTED SHARES AND RESTRICTED SHARE UNITS
Remuneration Information Classification · 95% confidence The document is an announcement from Zai Lab Limited regarding the grant of restricted shares and restricted share units to directors and an executive officer under the 2022 Equity Incentive Plan. It details the number of shares granted, vesting periods, and compliance with listing rules. The content focuses on share-based compensation awards to directors and executives, which is a form of remuneration information. There is no financial performance data, earnings, or report publication mentioned. The document is not a full report but an announcement of share grants related to executive compensation. Therefore, the most appropriate classification is Remuneration Information (DEF 14A).
2023-06-30 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.